Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

© Wiley

This Expert Insights eBook shares comprehensive knowledge on bispecific antibody (bsAb) development and explores how advancements in antibody engineering and bioprocessing are driving more effective immunotherapy treatments.

What you will learn:

• Bispecific antibody engineering: dual-targeting approaches in immunotherapy and cancer treatment
• Purification strategies and challenges: using mixed-mode chromatography to address the complexity of bsAb separation
• Advanced bioanalytical tools: including ddPCR technology, flow cytometry, and more!

More Information

Bispecific antibodies (bsAbs) represent a groundbreaking advancement in immunotherapy, offering the potential to revolutionize treatment for various diseases, including cancer, autoimmune, and inflammatory conditions. Their unique ability to engage two different antigens simultaneously enhances therapeutic efficacy and reduces dosage requirements. The development and optimization of bsAbs involves complex processes, from target identification to bioprocessing and manufacturing, which are crucial for improving productivity, selectivity, and overall therapeutic outcomes. This expert insights into bsAb development provides valuable knowledge for overcoming challenges and advancing the field, ultimately leading to more effective and accessible treatments for patients.

Article digests contained in the collection:

• Carver, J. et al. (2020). Maximizing antibody production in a targeted integration host by optimization of subunit gene dosage and position. Biotechnology Progress. https://doi.org/10.1002/btpr.2967.
• Parasnavis, S.S. et al. (2022). Systematic workflow for studying domain contributions of bispecific antibodies to selectivity in multimodal chromatography. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.27967.